logo conference-reports

Conference Reports

При финансовой поддержке logo MSD Oncology

ESMO 2019 — Trametinib tackles chemoresistance in recurrent/progressive low-grade serous ovarian or peritoneal cancer

Possibly a new standard of care for these carcinomas.